Physician profile
Melanie Sinatra
NPI 1043245954
$6,174.13
in general payments reported to CMS, 2019-2025
28 companies · $1,197 in 2025
The $1,197 reported for 2025 was more than what 93% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $724 · 2020: $882 · 2021: $558 · 2022: $987 · 2023: $871 · 2024: $954 · 2025: $1,197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,023.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,023.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $1,636.09 | 2019-2025 | Tecnis Iol, Catalys System, Tecnis Iol |
| Glaukos Corporation | $854.43 | 2019-2023 | Istent Infinite Trabecular Micro-Bypass System Model Is3, Is3-Istent Infinitetrabecular Micro-Bypass System Model Is3 |
| Alcon Vision LLC | $743.22 | 2019-2025 | Clareon, Tryptyr, Rocklatan |
| Abbvie INC. | $554.86 | 2022-2025 | Vuity |
| Rxsight INC | $315.15 | 2023-2024 | Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece |
| Sun Pharmaceutical Industries INC. | $284.07 | 2021-2025 | Cequa |
| Biotissue Holdings INC. | $206.90 | 2019-2025 | |
| Allergan, INC. | $195.86 | 2019-2022 | |
| Oyster Point Pharma, INC. | $171.99 | 2022-2024 | Tyrvaya |
| Bausch & Lomb Americas INC. | $162.82 | 2022-2025 | Envista Mx60 Iol, Miebo, Vyzulta |
| Tarsus Pharmaceuticals, INC. | $151.91 | 2024-2025 | Xdemvy |
| Sight Sciences, INC. | $139.61 | 2020-2025 | Sion Surgical Instrument, Omni Surgical System |
| New World Medical,INC. | $124.95 | 2019-2020 | |
| Aerie Pharmaceuticals, INC. | $98.39 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $81.26 | 2019-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ocular Therapeutix, INC. | $73.10 | 2021-2025 | Dextenza |
| Eyevance Pharmaceuticals LLC | $68.70 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $52.89 | 2019-2022 | |
| Dompe US, INC. | $48.57 | 2022-2024 | Oxervate |
| Cumberland Pharmaceuticals, INC. | $46.89 | 2022-2025 | Caldolor |
| Kala Pharmaceuticals, INC. | $39.48 | 2021-2022 | |
| Horizon Therapeutics Plc | $28.00 | 2023 | Tepezza |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Alcon Research LLC | $19.25 | 2019 | |
| Shire North American Group INC | $14.68 | 2019 | |
| Hologic Sales and Service, LLC | $14.29 | 2022 | |
| Omeros Corporation | $13.82 | 2019 | |
| Mallinckrodt Hospital Products INC. | $13.55 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melanie Sinatra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.